Skip to main content
Top
Published in: Pathology & Oncology Research 2/2015

01-04-2015 | Research

Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms

Authors: Heidi V. N. Küsters-Vandevelde, Ilse A. C. H. van Engen- van Grunsven, Sarah E. Coupland, Sarah L. Lake, Jos Rijntjes, Rolph Pfundt, Benno Küsters, Pieter Wesseling, Willeke A. M. Blokx, Patricia J. T. A. Groenen

Published in: Pathology & Oncology Research | Issue 2/2015

Login to get access

Abstract

Limited data is available on the genetic features of primary leptomeningeal melanocytic neoplasms (LMNs). Similarities with uveal melanoma were recently suggested as both entities harbor oncogenic mutations in GNAQ and GNA11. Whether primary LMNs share additional genetic alterations with uveal melanoma including copy number variations is unknown. Twenty primary LMNs ranging from benign and intermediate-grade melanocytomas to melanomas were tested by direct sequencing for hotspot mutations in the genes GNA11, GNAQ, BRAF, NRAS and HRAS. Furthermore, the lesions were tested for copy number variations of chromosomes frequently present in uveal melanoma (1p, 3, 6 and 8q) by multiplex ligation-dependent probe amplification (MLPA). Genome-wide analyses of copy number alterations of two leptomeningeal melanocytic neoplasms were performed using the OncoScan SNP-array. GNAQQ209 mutations were present in eleven LMNs, while two of 20 cases carried a GNA11Q209 mutation. No BRAF, HRAS or NRAS hotspot mutations were detected. Monosomy 3 and gain of 8q were present in one leptomeningeal melanoma, and one intermediate-grade melanocytoma harbored a gain of chromosome 6. With MLPA, the melanocytomas did not show any further gross chromosomal variations. Our data shows that primary LMNs, like uveal melanoma, harbor oncogenic mutations in GNAQ and GNA11 but lack mutations in BRAF, NRAS and HRAS. This finding may help in the differential diagnosis between a primary LMN and a metastasis from a cutaneous melanoma to the central nervous system. Copy number variations in some aggressive LMNs resemble those present in uveal melanoma but their prognostic significance is unclear.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brat DJ, Perry A (2007) Melanocytic lesions. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 181–183 Brat DJ, Perry A (2007) Melanocytic lesions. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 181–183
2.
go back to reference Bydon A, Gutierrez JA, Mahmood A (2003) Meningeal melanocytoma: an aggressive course for a benign tumor. J Neurooncol 64:259–263CrossRefPubMed Bydon A, Gutierrez JA, Mahmood A (2003) Meningeal melanocytoma: an aggressive course for a benign tumor. J Neurooncol 64:259–263CrossRefPubMed
3.
go back to reference Liubinas SV, Maartens N, Drummond KJ (2010) Primary melanocytic neoplasms of the central nervous system. J Clin Neurosci 17:1227–1232CrossRefPubMed Liubinas SV, Maartens N, Drummond KJ (2010) Primary melanocytic neoplasms of the central nervous system. J Clin Neurosci 17:1227–1232CrossRefPubMed
4.
go back to reference Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF (2010) Malignant transformation of intramedullary melanocytoma: case report. Neurosurg 67:867–869CrossRef Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF (2010) Malignant transformation of intramedullary melanocytoma: case report. Neurosurg 67:867–869CrossRef
5.
go back to reference Uozumi Y, Kawano T, Kawaguchi T, Kaneko Y, Ooasa T, Ogasawara S, Yoshida H, Yoshida T (2003) Malignant transformation of meningeal melanocytoma: a case report. Brain Tumor Pathol 20:21–5 Uozumi Y, Kawano T, Kawaguchi T, Kaneko Y, Ooasa T, Ogasawara S, Yoshida H, Yoshida T (2003) Malignant transformation of meningeal melanocytoma: a case report. Brain Tumor Pathol 20:21–5
6.
go back to reference Brat DJ, Giannini C, Scheithauer BW, Burger PC (1999) Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol 23:745–754CrossRefPubMed Brat DJ, Giannini C, Scheithauer BW, Burger PC (1999) Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol 23:745–754CrossRefPubMed
7.
go back to reference Arunkumar MJ, Ranjan A, Jacob M, Rajshekhar V (2001) Neurocutaneous melanosis: a case of primary intracranial melanoma with metastasis. Clin Oncol (R Coll Radiol) 13:52–54 Arunkumar MJ, Ranjan A, Jacob M, Rajshekhar V (2001) Neurocutaneous melanosis: a case of primary intracranial melanoma with metastasis. Clin Oncol (R Coll Radiol) 13:52–54
8.
go back to reference Koenigsmann M, Jautzke G, Unger M, Theallier-Janko A, Wiegel T, Stoltenburg-Didinger G (2002) 57-year-old male with leptomeningeal and liver tumors. Brain Pathol 12:519–521CrossRefPubMed Koenigsmann M, Jautzke G, Unger M, Theallier-Janko A, Wiegel T, Stoltenburg-Didinger G (2002) 57-year-old male with leptomeningeal and liver tumors. Brain Pathol 12:519–521CrossRefPubMed
9.
go back to reference Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA (2009) Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 119:317–23CrossRefPubMedCentral Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA (2009) Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 119:317–23CrossRefPubMedCentral
10.
go back to reference Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A, Pietsch T (2012) GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 39:417–25CrossRef Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A, Pietsch T (2012) GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 39:417–25CrossRef
11.
go back to reference Fuld AD, Speck ME, Harris BT, Simmons NE, Corless CL, Tsongalis GJ, Pastel DA, Hartford AC, Ernstoff MS (2011) Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. J Clin Oncol 29:499–502CrossRef Fuld AD, Speck ME, Harris BT, Simmons NE, Corless CL, Tsongalis GJ, Pastel DA, Hartford AC, Ernstoff MS (2011) Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. J Clin Oncol 29:499–502CrossRef
12.
go back to reference Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49:5230–5234CrossRefPubMedCentralPubMed Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49:5230–5234CrossRefPubMedCentralPubMed
13.
go back to reference Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602CrossRefPubMedCentralPubMed Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602CrossRefPubMedCentralPubMed
14.
go back to reference Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC A, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I et al (2010) Mutations in GNA11 in Uveal Melanoma. N Engl J Med 363:2191–9CrossRefPubMedCentralPubMed Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC A, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I et al (2010) Mutations in GNA11 in Uveal Melanoma. N Engl J Med 363:2191–9CrossRefPubMedCentralPubMed
15.
go back to reference Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardell A (2009) Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833CrossRefPubMedCentralPubMed Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardell A (2009) Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833CrossRefPubMedCentralPubMed
16.
go back to reference Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H (2000) Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res 7:111–120CrossRefPubMed Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H (2000) Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res 7:111–120CrossRefPubMed
17.
go back to reference Markby DW, Onrust R, Bourne HR (1993) Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 262:1895–1901 Markby DW, Onrust R, Bourne HR (1993) Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 262:1895–1901
19.
go back to reference Murali R, Wiesner T, Rosenblum MK, Bastian BC (2012) GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol 123:457–9CrossRefPubMedCentralPubMed Murali R, Wiesner T, Rosenblum MK, Bastian BC (2012) GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol 123:457–9CrossRefPubMedCentralPubMed
20.
go back to reference Strom RG, Shvartsbeyn M, Rosenblum MK, Hameed MR, Nafa K, Mikolaenko I, Babu RP (2012) Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma. Clin Neurol Neurosurg 114:1197–200CrossRefPubMed Strom RG, Shvartsbeyn M, Rosenblum MK, Hameed MR, Nafa K, Mikolaenko I, Babu RP (2012) Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma. Clin Neurol Neurosurg 114:1197–200CrossRefPubMed
21.
go back to reference Damato B, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16:6083–6092CrossRefPubMed Damato B, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16:6083–6092CrossRefPubMed
22.
go back to reference Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225CrossRefPubMed Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225CrossRefPubMed
23.
go back to reference van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HEHE et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317CrossRefPubMed van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HEHE et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317CrossRefPubMed
24.
go back to reference Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin A, Krahe R, Tuna M, Thompson PA et al (2009) High quality copy number and genotype data from FFPE samples using molecular inversion probe (MIP) microarrays. BMC Med Genomics 2:8CrossRefPubMedCentralPubMed Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin A, Krahe R, Tuna M, Thompson PA et al (2009) High quality copy number and genotype data from FFPE samples using molecular inversion probe (MIP) microarrays. BMC Med Genomics 2:8CrossRefPubMedCentralPubMed
25.
go back to reference Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A (2009) Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 101:813–815CrossRefPubMedCentralPubMed Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A (2009) Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 101:813–815CrossRefPubMedCentralPubMed
26.
go back to reference Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A (2013) Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer 109:493–496CrossRefPubMedCentralPubMed Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A (2013) Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer 109:493–496CrossRefPubMedCentralPubMed
27.
go back to reference Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V (2011) Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 52:7248–7255CrossRefPubMedCentralPubMed Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V (2011) Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 52:7248–7255CrossRefPubMedCentralPubMed
28.
go back to reference Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS (2012) The protein kinase C inhibitor enzastaurin exhibits antitumor activity against Uveal Melanoma. PLoS One 7:e29622CrossRefPubMedCentralPubMed Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS (2012) The protein kinase C inhibitor enzastaurin exhibits antitumor activity against Uveal Melanoma. PLoS One 7:e29622CrossRefPubMedCentralPubMed
29.
go back to reference von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A (2012) Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11:22CrossRef von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A (2012) Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11:22CrossRef
30.
go back to reference Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE (2012) Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Canc Res 18:4345–4355CrossRef Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE (2012) Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Canc Res 18:4345–4355CrossRef
31.
go back to reference Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK (2012) Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439CrossRefPubMedCentralPubMed Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK (2012) Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439CrossRefPubMedCentralPubMed
32.
go back to reference Carjaval RD. Quevedo F. et al. (2013) Phase II study of selumetinib versus temozolomide in gnaq/gna11 mutation uveal melanoma. In: 2013 ASCO Annual Meeting Carjaval RD. Quevedo F. et al. (2013) Phase II study of selumetinib versus temozolomide in gnaq/gna11 mutation uveal melanoma. In: 2013 ASCO Annual Meeting
33.
go back to reference Chen X. Wu Q. Tan L. Porter D. Jager MJ. C. Emery C. B.C. Bastian BC (2013) Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene doi: 10.1038/onc.2013.418 Chen X. Wu Q. Tan L. Porter D. Jager MJ. C. Emery C. B.C. Bastian BC (2013) Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene doi: 10.1038/onc.2013.418
34.
go back to reference Wang H, Zhang S, Wu C, Zhang Z, Qin T (2013) Melanocytomas of the central nervous system: a clinicopathological and molecular study. Eur J Clin Invest 43:809–15CrossRefPubMed Wang H, Zhang S, Wu C, Zhang Z, Qin T (2013) Melanocytomas of the central nervous system: a clinicopathological and molecular study. Eur J Clin Invest 43:809–15CrossRefPubMed
35.
go back to reference Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Kusters B, Wesseling P, Blokx WA, Marais R (2013) Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 3:458–469CrossRefPubMedCentralPubMed Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Kusters B, Wesseling P, Blokx WA, Marais R (2013) Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 3:458–469CrossRefPubMedCentralPubMed
36.
go back to reference Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Slater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 133:2229–36CrossRefPubMedCentralPubMed Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Slater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 133:2229–36CrossRefPubMedCentralPubMed
37.
go back to reference Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:515–520CrossRefPubMed Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:515–520CrossRefPubMed
38.
go back to reference Greco Crasto S, Soffietti R, Bradac GB, Boldorini R (2001) Primitive cerebral melanoma: case report and review of the literature. Surg Neurol 55:163–168CrossRefPubMed Greco Crasto S, Soffietti R, Bradac GB, Boldorini R (2001) Primitive cerebral melanoma: case report and review of the literature. Surg Neurol 55:163–168CrossRefPubMed
39.
go back to reference Theunissen P, Spincemaille G, Pannebakker M, Lambers J (1993) Meningeal melanoma associated with nevus of Ota: case report and review. Clin Neuropathol 12:125–129PubMed Theunissen P, Spincemaille G, Pannebakker M, Lambers J (1993) Meningeal melanoma associated with nevus of Ota: case report and review. Clin Neuropathol 12:125–129PubMed
40.
go back to reference Rodriguez y Baena R, Gaetani P, Danova M, Bosi F, Zappoli F (1992) Primary solitary intracranial melanoma: case report and review of the literature. Surgical Neurol 38:26–37CrossRef Rodriguez y Baena R, Gaetani P, Danova M, Bosi F, Zappoli F (1992) Primary solitary intracranial melanoma: case report and review of the literature. Surgical Neurol 38:26–37CrossRef
41.
go back to reference Skarli SO, Wolf AL, Kristt DA, Numaguch Y (1994) Melanoma arising in a cervical spinal nerve root: report of a case with a benign course and malignant features. Neurosurg 34:533–537CrossRef Skarli SO, Wolf AL, Kristt DA, Numaguch Y (1994) Melanoma arising in a cervical spinal nerve root: report of a case with a benign course and malignant features. Neurosurg 34:533–537CrossRef
42.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed
43.
go back to reference Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, Scolyer RA, Spatz A, Bastian BC (2010) Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 23:763–770CrossRefPubMedCentralPubMed Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, Scolyer RA, Spatz A, Bastian BC (2010) Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 23:763–770CrossRefPubMedCentralPubMed
44.
go back to reference van den Bosch BT, Kilic E, Paridaens D, de Klein A (2010) Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 360136 van den Bosch BT, Kilic E, Paridaens D, de Klein A (2010) Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 360136
45.
go back to reference Parrella P, Sidransky D, Merbs SL (1999) Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 59:3032–3037PubMed Parrella P, Sidransky D, Merbs SL (1999) Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 59:3032–3037PubMed
46.
go back to reference Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761–5766PubMed Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761–5766PubMed
47.
go back to reference Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, de Klein A (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14:203–205CrossRefPubMed Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, de Klein A (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14:203–205CrossRefPubMed
48.
go back to reference Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 83:1771–1776CrossRefPubMed Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 83:1771–1776CrossRefPubMed
49.
go back to reference Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99:1673–1677CrossRefPubMedCentralPubMed Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99:1673–1677CrossRefPubMedCentralPubMed
Metadata
Title
Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms
Authors
Heidi V. N. Küsters-Vandevelde
Ilse A. C. H. van Engen- van Grunsven
Sarah E. Coupland
Sarah L. Lake
Jos Rijntjes
Rolph Pfundt
Benno Küsters
Pieter Wesseling
Willeke A. M. Blokx
Patricia J. T. A. Groenen
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9841-3

Other articles of this Issue 2/2015

Pathology & Oncology Research 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine